# Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

> **NCT07223814** · PHASE3 · RECRUITING · sponsor: **Stichting Hemato-Oncologie voor Volwassenen Nederland** · enrollment: 875 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Bleximenib
- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin or Idarubicin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07223814
- **Lead sponsor:** Stichting Hemato-Oncologie voor Volwassenen Nederland
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2030-06
- **Final completion:** 2033-12
- **Target enrollment:** 875 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07223814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07223814, "Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07223814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*